CALL/NOVO-NORDISK B/1400/0.01/20.06.25 | Real-time BOERSE MUENCHEN 06:27:32 2024-06-12 EDT | ||
| 0.05 EUR | +2.04% |
|
| Current month | +28.95% | ||
| 1 month | +58.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-12 | 0.05 | +2.04% |
| 24-06-11 | 0.049 | -5.77% |
| 24-06-10 | 0.052 | +8.33% |
| 24-06-07 | 0.048 | +4.35% |
| 24-06-06 | 0.046 | +9.52% |
Real-time BOERSE MUENCHEN
Last update June 12, 2024 at 06:27 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GG7D9Q |
| ISIN | DE000GG7D9Q5 |
| Date issued | 2024-04-22 |
| Strike | 1,400 kr |
| Maturity | 2025-06-20 (374 Days) |
| Parity | 100 : 1 |
| Emission price | 0.03 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.052 € |
|---|---|
| Lowest since issue | 0.027 € |
| Spread | 0.01 € |
| Spread % | 16.67% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
982
DKK
Average target price
929.5
DKK
Spread / Average Target
-5.35%
- Stock Market
- Warrants
- Warrant
